Deferred Income Tax Assets, Net of VERTEX PHARMACEUTICALS INC / MA from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Deferred Income Tax Assets, Net in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • VERTEX PHARMACEUTICALS INC / MA Deferred Income Tax Assets, Net for the quarter ending 30 Sep 2025 was $2,937,200,000, a 27% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Deferred Income Tax Assets, Net (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,937,200,000 +$628,300,000 +27% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $2,711,700,000 +$526,100,000 +24% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $2,544,300,000 +$581,300,000 +30% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $2,331,100,000 +$519,000,000 +29% 31 Dec 2024 10-Q 04 Nov 2025 2025 Q3
Q3 2024 $2,308,900,000 +$579,800,000 +34% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $2,185,600,000 +$647,600,000 +42% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $1,963,000,000 +$603,100,000 +44% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $1,812,100,000 +$565,200,000 +45% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $1,729,100,000 +$566,400,000 +49% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $1,538,000,000 +$394,200,000 +34% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $1,359,900,000 +$414,400,000 +44% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $1,246,900,000 +$312,400,000 +33% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $1,162,700,000 +$228,861,000 +25% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $1,143,800,000 +$190,992,000 +20% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $945,500,000 +$129,610,000 +16% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $934,500,000 +$51,700,000 +5.9% 31 Dec 2021 10-K 10 Feb 2023 2022 FY
Q3 2021 $933,839,000 -$213,977,000 -19% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $952,808,000 -$262,160,000 -22% 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $815,890,000 -$331,815,000 -29% 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $882,800,000 -$308,015,000 -26% 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q3 2020 $1,147,816,000 -$267,695,000 -19% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $1,214,968,000 -$210,223,000 -15% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $1,147,705,000 -$319,813,000 -22% 31 Mar 2020 10-Q 01 May 2020 2020 Q1
Q4 2019 $1,190,815,000 -$308,857,000 -21% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $1,415,511,000 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $1,425,191,000 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $1,467,518,000 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $1,499,672,000 31 Dec 2018 10-K 13 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.